Aimmune Therapeutics announces proposed public offering of common stock
Aimmune Therapeutics announced it has commenced an underwritten public offering of up to $150,000,000 of shares of its common stock. Aimmune expects to grant underwriters of the offering a 30-day option to purchase up to an additional $22,500,000 of shares of common stock. February 20, 2018